UNSPSC 51112104: Etoglucid

This classification denotes an antineoplastic alkylating agent with the molecular formula C12H22O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F9KUA0T4D, chemically known as 4,7,10,13-tetraoxahexadecane, 1,2:15,16-diepoxy- (8ci) but more generally known as etoglucid, which bears US NIH Compound Identifier 16058. European Medicines Agency schedules Etoglucid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07326MIG. The term ETOGLUCID is an International Non-Proprietary Name.

UNSPSC 51112104 Etoglucid, a Commodity code, covers pharmaceutical products sourced through state and local health agencies' prescription benefit and direct-purchasing programs. Recent state and local activity under this code reflects a shift toward direct-to-manufacturer procurement models that bypass traditional pharmacy benefit managers and group purchasing organizations. The Texas Health and Human Services Commission exemplifies this trend, soliciting vendor capabilities for implementing direct manufacturer relationships to improve prescription fulfillment efficiency and manage costs through negotiated net pricing and outcomes-based agreements. State health agencies and self-insured employee benefit plans issuing under this code seek vendors experienced in direct contracting for pharmaceutical supply, with flexibility to negotiate alternative pricing models and volume fulfillment strategies outside conventional wholesaler and PBM channels.

Texas represents the primary recent activity under the code. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) on April 3, 2026, to gather market intelligence on Direct-to-Manufacturer Prescriptions program implementation, seeking vendor experience with direct contracting for self-insured employers and government health plans, participation in multi-jurisdictional government purchasing organizations, and capability to implement value-based or outcomes-based prescription agreements. The RFI functions as an exploratory procurement mechanism to inform the state's future formal solicitation strategy rather than a binding competitive round; no award values, budget ranges, or set-aside designations were identified at this information-gathering stage, and the state indicated it will develop detailed procurement specifications and formal RFP terms following vendor response analysis.